Affimed (AFMD) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Affimed (AFMD) Misses Q2 EPS by 2c
August 4, 2015 7:30 AM EDT
--Management provides update on clinical programs and advance of unique immunotherapy approach for cancer-- Â
HEIDELBERG, Germany, Aug. 4, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today reported financial results for the quarter ended June 30, 2015.
"Over this past quarter we have presented exciting data that demonstrates the potential of our unique NK-cell engaging approach, in particular preclinical data showing that our lead program AFM13 has therapeutic synergy in combination with checkpoint inhibitors," said Dr. Adi Hoess, CEO of Affimed. "The recent follow-on financing further... More
August 4, 2015 7:30 AM EDT
--Management provides update on clinical programs and advance of unique immunotherapy approach for cancer-- Â
HEIDELBERG, Germany, Aug. 4, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today reported financial results for the quarter ended June 30, 2015.
"Over this past quarter we have presented exciting data that demonstrates the potential of our unique NK-cell engaging approach, in particular preclinical data showing that our lead program AFM13 has therapeutic synergy in combination with checkpoint inhibitors," said Dr. Adi Hoess, CEO of Affimed. "The recent follow-on financing further... More
